Relapses of acute lymphoblastic leukemia in children with t(1;19)(q23;p13) translocation: a case series
Pediatric Hematology/Oncology and Immunopathology · 14.04.2026 · 25 (1) · 145-150
DOI: 10.24287/j.1005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 14.04.2026. Verfasst von K. I. Amelina und 8 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
The (1;19)(q23;p13) translocation, which generates the TCF3::PBX1 fusion gene, is detected in 3–5% of patients with acute lymphoblastic leukemia (ALL). In cases of relapse, the disease often demonstrates aggressive and refractory behavior, including the development of extramedullary sites. Defining the optimal sequence and combination of therapeutic approaches in this genetic subgroup requires further investigation and standardization on the basis of accumulated clinical data. Aim: to describe the clinical patterns of ALL relapse in children with the (1;19)(q23;p13) translocation and to analyze outcomes according to relapse site and disease course. Materials and methods. We conducted a retrospective descriptive analysis of seven pediatric ALL relapse cases harboring the (1;19)(q23;p13) translocation. We analyzed the clinical manifestations of relapses, the sequence of salvage therapy, and outcomes at last follow-up. For a more detailed analysis, two cases with opposite outcomes were selected: one with a durable second remission and another with a progressive, incurable disease.
Results
At the time of analysis, sustained remission was achieved in only 1 out of 7 patients. In 3 cases, treatment options were exhausted and these patients were transitioned to a palliative level of care. At the time of manuscript preparation, 2 patients were undergoing hematopoietic stem cell transplantation, and 1 patient was receiving maintenance therapy.
Conclusion
This case series highlights the need for individualized management of relapsed ALL in this genetic subgroup, including targeted and cell therapies, local control strategies, and updating risk stratification models.
Zitieren
APA
Amelina, K. I., Dyakonova, Y. Y., Vavilova, L. A., Abugova, Y. G., Chugaeva, L. K., Evstratov, D. A., Shelikhova, L. N., Khachatryan, L. A., & Myakova, N. V. (2026). Relapses of acute lymphoblastic leukemia in children with t(1;19)(q23;p13) translocation: a case series. Pediatric Hematology/Oncology and Immunopathology, 25(1), 145-150. https://doi.org/10.24287/j.1005
Vancouver
Amelina KI, Dyakonova YY, Vavilova LA, Abugova YG, Chugaeva LK, Evstratov DA, et al. Relapses of acute lymphoblastic leukemia in children with t(1;19)(q23;p13) translocation: a case series. Pediatric Hematology/Oncology and Immunopathology. 2026;25(1):145-150. doi:10.24287/j.1005
BibTeX
@article{Amelina2026,
author = {Amelina, K. I. and Dyakonova, Y. Y. and Vavilova, L. A. and Abugova, Y. G. and Chugaeva, L. K. and Evstratov, D. A. and Shelikhova, L. N. and Khachatryan, L. A. and Myakova, N. V.},
title = {Relapses of acute lymphoblastic leukemia in children with t(1;19)(q23;p13) translocation: a case series},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {1},
pages = {145--150},
doi = {10.24287/j.1005}
}
EUVIMED